RobertHauserMD

Neurology • Tampa, FL

Movement Disorder

Professor of Neurology, University S Fla College of Medicine

Join to view full profile

Dr. Hauser is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hauser's full profile

Already have an account?

Office
4001 E Fletcher Ave, 6th Fl
Parkinson's Disease/Movement Disorders Ctr
Tampa, FL 33613
Phone+1 813-396-0751

Fax+1 813-905-9829
Is this information wrong?

Summary

Dr. Robert Hauser is Director of the Parkinson's Disease and Movement Disorders Center of the University of South Florida. He received his medical degree from Temple University School of Medicine and has been in practice 31 years. He specializes in Parkinson's disease and is an expert in clinical research to develop new treatments for Parkinson's disease and related disorders. He also performs Botox injections for cervical dystonia, blepharospasm, and hemifacial spasm. He has published over 300 peer reviewed articles and lectures frequently at scientific meetings.

Education & Training

Eastern Virginia Medical SchoolResidency, Neurology, 1983 - 1988
Albert Einstein Medical CenterInternship, Transitional Year, 1982 - 1983
Lewis Katz School of Medicine at Temple UniversityClass of 1982

Certifications & Licensure

FL State Medical License 1989 - 2024
CA State Medical License 1986 - 1992
PA State Medical License 1988 - 1990
MI State Medical License 1988 - 1990
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly

Clinical Trials

Keppra for Cervical Dystonia Start of enrollment: 2005 Nov 01
Terminated
Phase 2
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease Start of enrollment: 2009 Mar 01
Unknown status
Phase 3
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 2
Glutathione (GSH) In The Treatment of Parkinson's Disease Start of enrollment: 2003 Sep 01
Completed
Phase 2
Parkinson's Foundation Quality Improvement Initiative Start of enrollment: 2009 Jul 01
Recruiting
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease Start of enrollment: 2013 Mar 01
Terminated
Phase 2
A Study to Examine APL-130277 in Patients With Parkinson's Disease Start of enrollment: 2014 Aug 31
Completed
Phase 2
A Study to Assess the Safety and Efficacy of the of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Start of enrollment: 2016 Mar 01
Unknown status
Phase 3
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis Start of enrollment: 2016 Dec 31
Completed
Phase 2
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Start of enrollment: 2017 Jan 01
Completed
Phase 2
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
Recruiting
Phase 3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations Start of enrollment: 2020 Oct 27
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial.
Robert A Hauser, Alberto J Espay, Aaron L Ellenbogen, Hubert H Fernandez, Stuart H Isaacson, Peter A LeWitt, William G Ondo, Rajesh Pahwa, Johannes Schwarz, Fabrizio S...> ;JAMA Neurology. 2023 Aug 14
1 citations
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
Davide Martino, Vikram Karnik, Roongroj Bhidayasiri, Deborah A Hall, Robert A Hauser, Antonella Macerollo, Tamara M Pringsheim, Daniel Truong, Stewart A Factor, Matej ...> ;Movement Disorders. 2023 Jun 1
Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson's Disease: Is the Prophylactic Use of an Antiemetic Necessary?
Robert A Hauser, William G Ondo, Yi Zhang, Alyssa Bowling, Bradford Navia, Eric Pappert, Stuart H Isaacson> ;Journal of Parkinson's Disease. 2023 Jan 1
1 citations
The Clinical Development of Levodopa Inhalation Powder.
Robert A Hauser, Peter A LeWitt, Cheryl H Waters, Donald G Grosset, Burkhard Blank> ;Clinical Neuropharmacology. 2023 Jan 29
Dopamine agonists in Parkinson's disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment.
Stuart H Isaacson, Robert A Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri> ;Clinical Parkinsonism & Related Disorders. 2023 Jan 1
1 citations
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, p...
Michael J Soileau, Jason Aldred, Kumar Budur, Nahome Fisseha, Victor Sc Fung, Anna Jeong, Thomas E Kimber, Kevin Klos, Irene Litvan, Daniel O'Neill, Weining Z Robieson...> ;The Lancet. Neurology. 2022 Dec 1
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
Robert A Hauser, Nir Giladi, Werner Poewe, Jonathan Brotchie, Hadas Friedman, Sheila Oren, Pninit Litman> ;Advances in Therapy. 2022 May 1
1 citations
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
Robert A Hauser, Hadas Barkay, Amanda Wilhelm, Maria Wieman, Juha-Matti Savola, Mark Forrest Gordon> ;Parkinsonism & Related Disorders. 2022 Apr 1
3 citations
Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.
Robert A Hauser, Judy Lytle, Andrea E Formella, Caroline M Tanner> ;NPJ Parkinson's Disease. 2022 Mar 18
1 citations
Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.
Robert A Hauser, Antonella Favit, L Arthur Hewitt, Annika Lindsten, Stephen Gorny, Steven Kymes, Stuart H Isaacson> ;Neurology and Therapy. 2022 Mar 1
3 citations
Abbreviated MDS-UPDRS for Remote Monitoring in PD Identified Using Exhaustive Computational Search.
Gareth Morinan, Robert A Hauser, Anette Schrag, Jingxuan Tang, Jonathan O'Keeffe, Mds-Nms Scale Development Study Group> ;Parkinson's Disease. 2022 Jan 1
1 citations
Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.
Robert A Hauser, Santosh Goud, Andrea E Formella> ;Clinical Parkinsonism & Related Disorders. 2022 Jan 1
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
Rajesh Pahwa, Susan Fox, Robert A Hauser, Stuart Isaacson, Judy Lytle, Reed Johnson, Lily Llorens, Andrea E Formella, Caroline M Tanner> ;Frontiers in Neurology. 2022 Jan 1
3 citations
Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum...
Cynthia Comella, Robert A Hauser, Stuart H Isaacson, Daniel Truong, Odinachi Oguh, Jennifer Hui, Eric S Molho, Matthew Brodsky, Erin Furr-Stimming, Georg Comes, Michae...> ;Clinical Parkinsonism & Related Disorders. 2022 Jan 1
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Stewart A Factor, Joohi Jimenez-Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Jessica Alexander, Mark Fo...> ;Frontiers in Neurology. 2022 Jan 1
23 citations
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Tamara Pringsheim, Gregory S. Day, Don B. Smith, Alex Rae-Grant, Nicole Licking, Melissa J. Armstrong, Rob M.A. de Bie, Emmanuel Roze, Janis M. Miyasaki, Robert A. Hau...> ;Neurology. 2021 Nov 16
50 citations
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
Michael A. Schwarzschild, Alberto Ascherio, Cindy Casaceli, Gary C. Curhan, Rebecca Fitzgerald, Cornelia Kamp, Codrin Lungu, Eric A. Macklin, Kenneth Marek, Dariush Mo...> ;JAMA. 2021 Sep 14
8 citations
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.
Robert A. Hauser, Nobutaka Hattori, Hubert H. Fernandez, Stuart Isaacson, Hideki Mochizuki, Olivier Rascol, Fabrizio Stocchi, June Li, Akihisa Mori, Yu Nakajima, Rober...> ;Journal of Parkinson's Disease. 2021 Jan 1
13 citations
A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease.
Samuel Rupprechter, Gareth Morinan, Yuwei Peng, Thomas Foltynie, Krista G. Sibley, Rimona S. Weil, Louise-Ann Leyland, Fahd Baig, Francesca Morgante, Roee Gilron, Robe...> ;Sensors. 2021 Aug 1
3 citations
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
Aleksandar Videnovic, Amy W. Amara, Cynthia L. Comella, Paula K. Schweitzer, Helene A. Emsellem, Kris Liu, Amanda L. Sterkel, Mildred D. Gottwald, Joshua R. Steinerman...> ;Movement Disorders. 2021 Jun 30
9 citations
On demand therapy for Parkinson's disease patients: Opportunities and choices.
Robert A. Hauser, Peter A. LeWitt, Cynthia L. Comella> ;Postgraduate Medicine. 2021 Jun 30
1 citations
Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
Robert A. Hauser, Shyamal H. Mehta, Daniel Kremens, Dustin Chernick, Andrea E. Formella> ;Neurology and Therapy. 2021 May 22
4 citations
Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.
Shyamal H. Mehta, Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Reed Johnson> ;Neurology and Therapy. 2021 Apr 17
11 citations
Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America
Anna Naito, Anne-Marie Wills, Thomas F. Tropea, Adolfo Ramirez-Zamora, Robert A. Hauser, Davide Martino, Travis H. Turner, Miriam R. Rafferty, Mitra Afshari, Karen Wil...> ;NPJ Parkinson's Disease. 2021 Apr 12
Minimal Clinically Important Difference in AIMS Score Based on CGIC and PGIC in Patients With Tardive Dyskinesia Treated With Deutetrabenazine.
Hadas Barkay, Robert A. Hauser, Amanda Wilhelm, Maria Wieman, Mark Forrest Gordon, Juha-Matti Savola> ;Cns Spectrums. 2021 Apr 1
Join now to see all

Journal Articles

Therapeutic Strategies for Parkinson Disease: Beyond Dopaminergic Drugs
Robert Hauser, MD, Nature
Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
Hubert H Fernandez, Robert A Hauser, The Lancet

Press Mentions

Pharma Two B Announces Positive Topline Results from Its Pivotal Phase III Study of P2B001 in Early Parkinson's DiseaseDecember 15th, 2021
Anatomy of an Industry: Commerce, Payments to Psychiatrists and Betrayal of the Public GoodSeptember 18th, 2021
PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021September 7th, 2021
Join now to see all